ANI Pharmaceuticals

In two facilities with combined manufacturing, packaging and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder and oral solid dose products, including those requiring containment. ANI also performs contract manufacturing for some of the largest and most respected pharmaceutical companies in the world. The fully-cGMP qualified facilities boast state-of-the-art analytical and stability laboratories for ANI's rapidly expanding research and development program. With several ANDAs pending FDA approval, and in various stages of development, ANI is poised for tremendous growth in the months and years to come!
Type
Public
HQ
Baudette, US
Size (employees)
143 (est)+33%
ANI Pharmaceuticals is headquartered in Baudette, US

ANI Pharmaceuticals Office Locations

ANI Pharmaceuticals has an office in Baudette
Baudette, US (HQ)
210 Main St W
Baudette, US
455 Idc Rd Sw

ANI Pharmaceuticals Data and Metrics

ANI Pharmaceuticals Financial Metrics

ANI Pharmaceuticals's revenue was reported to be $36.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

36.6 m

Gross profit (Q1, 2017)

20.2 m

Gross profit margin (Q1, 2017), %

55%

Net income (Q1, 2017)

1.2 m

EBIT (Q1, 2017)

4.6 m

Market capitalization (25-Jul-2017)

577.5 m

Cash (31-Mar-2017)

10.8 m
ANI Pharmaceuticals's current market capitalization is $577.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

30.1 m56 m76.3 m128.6 m

Revenue growth, %

86%36%69%

Cost of goods sold

10 m11.5 m12.7 m48.8 m

Gross profit

20.1 m44.5 m63.6 m79.8 m

Gross profit Margin, %

67%80%83%62%

R&D expense

2.9 m

Operating expense total

19.2 m24.5 m30.9 m108.5 m

EBIT

898 k20 m32.7 m20.1 m

EBIT margin, %

3%36%43%16%

Interest expense

467 k787 k11 m11.3 m

Net Income

301 k28.7 m15.4 m3.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

6.6 m17.4 m18.8 m19.5 m20 m20.6 m31.3 m38.5 m36.6 m

Cost of goods sold

2.1 m3.1 m2.8 m3.1 m3.3 m3.4 m11.8 m16.7 m16.4 m

Gross profit

4.5 m14.3 m16 m16.4 m16.7 m17.1 m19.5 m21.9 m20.2 m

Gross profit Margin, %

68%82%85%84%84%83%62%57%55%

R&D expense

851 k883 k403 k995 k815 k966 k764 k1 m1.6 m

General and administrative expense

5.4 m4.1 m4.8 m5.6 m5.4 m

Operating expense total

6.3 m4.9 m5.2 m6.5 m6.2 m966 k764 k1 m1.6 m

EBIT

(2.5 m)9.6 m8.5 m5.7 m5.2 m7.9 m4.6 m

EBIT margin, %

(37%)51%42%28%17%21%13%

Interest expense

(2.7 m)(2.8 m)(2.8 m)(2.9 m)(2.9 m)

Pre tax profit

6.9 m5.7 m2.9 m2.4 m5 m1.7 m

Income tax expense

(2.5 m)(1.1 m)(1.5 m)(1.2 m)(2.5 m)(523 k)

Net Income

6.7 m4.4 m3.6 m4.6 m1.3 m1.1 m2.5 m1.2 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

11.1 m169 m154.7 m27.4 m

Accounts Receivable

12.5 m17.3 m21.9 m45.9 m

Inventories

580 k1.1 m1.5 m26.2 m

Current Assets

27.7 m203.5 m192.6 m103 m

PP&E

4.5 m5.2 m7.1 m11 m

Goodwill

1.8 m1.8 m1.8 m1.8 m

Total Assets

44.5 m263.7 m285.3 m322.9 m

Accounts Payable

1.4 m2.7 m2.1 m3.4 m

Current Liabilities

3.5 m13.2 m11.8 m31.9 m

Total Liabilities

153.2 m

Additional Paid-in Capital

89.5 m159.5 m164.4 m172.6 m

Retained Earnings

(48.5 m)(19.7 m)(4.4 m)(2.9 m)

Total Equity

41 m139.8 m160.1 m169.6 m

Financial Leverage

1.1 x1.9 x1.8 x1.9 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

53 m35.1 m165.6 m166.7 m150.9 m77.7 m15 m16.2 m10.8 m

Inventories

5.9 m7.3 m10.7 m12.7 m13.7 m13.9 m25.1 m28.3 m45.9 m

Current Assets

67.2 m57.6 m203 m208.9 m197.5 m116.6 m79.8 m95.5 m107 m

PP&E

4.6 m5 m5.3 m5.2 m5.8 m8.4 m8.9 m9.7 m12.9 m

Goodwill

1.8 m1.8 m1.8 m1.8 m1.8 m1.8 m1.8 m1.8 m1.8 m

Total Assets

95.4 m107.6 m266 m270.1 m283.3 m291.6 m308 m319.4 m357.1 m

Accounts Payable

1.7 m3.1 m2.3 m1.3 m2.6 m3 m5 m4.7 m4.8 m

Current Liabilities

3.8 m8.1 m9.1 m6.9 m12.2 m16.2 m24.7 m30.5 m32.4 m

Additional Paid-in Capital

139.1 m140.2 m160.1 m161.4 m163.1 m165.7 m168.2 m170.7 m174 m

Retained Earnings

(47.5 m)(40.7 m)(15.4 m)(11.8 m)(7.2 m)(5.5 m)(4.4 m)(1.8 m)(1.8 m)

Total Equity

91.6 m99.5 m144.7 m149.5 m155.9 m160.2 m163.8 m168.8 m172.2 m

Financial Leverage

1 x1.1 x1.8 x1.8 x1.8 x1.8 x1.9 x1.9 x2.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

301 k28.7 m15.4 m3.9 m

Depreciation and Amortization

1.1 m3.9 m6.9 m22.3 m

Accounts Receivable

(7.1 m)(4.8 m)(4.6 m)(24 m)

Inventories

(708 k)(3.5 m)(314 k)(647 k)

Accounts Payable

(565 k)225 k(1 m)1.1 m

Cash From Operating Activities

11.1 m157.9 m(14.4 m)27.5 m

Purchases of PP&E

(191 k)(1.1 m)(2.2 m)(4.6 m)

Cash From Investing Activities

20.3 m(35.8 m)(32.7 m)(154.1 m)

Interest Paid

250 k4.2 m

Income Taxes Paid

147 k13.3 m9.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

6.7 m4.4 m3.6 m4.6 m1.3 m1.1 m2.5 m1.2 m

Depreciation and Amortization

706 k1.2 m1.3 m1.4 m2 m4.6 m6 m6 m6.7 m

Accounts Payable

1.7 m3.1 m2.3 m1.3 m2.6 m3 m5 m4.7 m4.8 m
USDY, 2017

Revenue/Employee

256.1 k

Financial Leverage

2.1 x

ANI Pharmaceuticals Market Value History

ANI Pharmaceuticals Company Life and Culture

You may also be interested in